# Trastuzumab

## Herceptin inj 440mg (Sample)

| 藥物代碼           | IHER0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 副作用             | Abdominal pain, accidental injury, asthenia, back pain, chest pain, chills, fever, flu syndrome, headache, infection, neck pain, vasodilation, GI disturbances, peripheral edema, edema, arthralgia, myalgia, anxiety, depression, dizziness, insomnia, paresthesia, somnolence, asthma, cough increased, dyspnea, epistaxis, lung disorders, pleural effusion, pharyngitis, rhinitis, sinusitis, pruritus, rash. Cardiovascular: Edema (8% monotherapy ), Peripheral edema (5% to 10% ), Tachycardia (5% monotherapy )Dermatologic: Rash (4% to 18% )Gastrointestinal: Abdominal pain (2% to 22% ), Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy ), Loss of appetite (14% monotherapy ), Nausea (6% to 33% ), Vomiting (3.5% to 23% )Hematologic: Anemia (4% ), Febrile neutropenia (23% adjuvant therapy ), Leukopenia (3% ), Neutropenia (32% grade 3/4; 2% grade 4/5 )Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy )Musculoskeletal: Backache (5% to 22% ), Myalgia (4% to 10% )Neurologic: Asthenia (4.5% to 42% ), Dizziness (4% to 13% ), Headache (6% to 26% ), Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy )Respiratory: Cough (2% to 26% ), Dyspnea (3% to 22% ), Pharyngitis (12% monotherapy ), Rhinitis (2% to 14% )Other: Fever (6% to 36% ) |
| 禁忌               | Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量           | Weekly schedule: Loading dose: 4 mg/kg as a 90-min IV infusion. Subsequent dose: 2 mg/kg weekly as a 30-min IV infusion. Alternative 3-weekly schedule: Initial loading dose of 8 mg/kg, followed by 6 mg/kg 3 weeks later & then 6 mg/kg repeated at 3-weekly intervals as infusion over approx 90 min. Duration for EBC: 1 year or until disease recurrence.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 孕期用藥建議       | Human data suggest risk in 2nd and 3rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 輸注點滴液         | 【N/S】 可選 仿單建議                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 注意事項           | 1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。 3. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 4. 監測CBC、肝腎功能。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## HERCEPTIN inj 600mg/5mL

| 藥物代碼           | IHER6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Breast cancer, adjuvant treatment, breast cancer, metastatic, gastric cancer, metastatic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用             | >10%:Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%)Central nervous system: Pain (47%), chills (5% to 32%), headache (10% to 26%), insomnia (14%), dizziness (4% to 13%)Dermatologic: Skin rash (4% to 18%)Gastrointestinal: Nausea (6% to 33%), diarrhea (7% to 25%), vomiting (4% to 23%), abdominal pain (2% to 22%), anorexia (14%)Infection: Infection (20%)Neuromuscular & skeletal: Weakness (4% to 42%), back pain (5% to 22%)Respiratory: Cough (5% to 26%), dyspnea (3% to 22%), rhinitis (2% to 14%), pharyngitis (12%)Miscellaneous: Infusion related reaction (21% to 40%, chills and fever most common; severe: 1%), fever (6% to 36%) |
| 禁忌               | Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 用法用量           | SC Metastatic Breast cancer & Early breast cancer 3-weekly: 600 mg fixed dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 孕期用藥建議       | Human data suggest risk in 2nd and 3rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 注射劑給藥建議途徑 | SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 注意事項           | 1.本品僅能以皮下注射給予。注射時間應為2-5分鐘。 2.不論患者體重多寡，本品之建議固定劑量為600mg，每3週給藥ㄧ次。 3.注射部位應在左右大腿之間輪替，新的注射部位與舊的注射部位應相距至少2.5公分，且不得在皮膚發紅、瘀青、觸痛或硬塊處注射。 4.第一次皮下注射後6小時以及後續的皮下注射後2小時，應觀察患者是否出現注射相關反應。                                                                                                                                                                                                                                                                                                                                                     |

## HERCEPTIN inj 600mg/5mL (sample)

| 藥物代碼           | IHER60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Breast cancer, adjuvant treatment, breast cancer, metastatic, gastric cancer, metastatic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用             | >10%:Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%)Central nervous system: Pain (47%), chills (5% to 32%), headache (10% to 26%), insomnia (14%), dizziness (4% to 13%)Dermatologic: Skin rash (4% to 18%)Gastrointestinal: Nausea (6% to 33%), diarrhea (7% to 25%), vomiting (4% to 23%), abdominal pain (2% to 22%), anorexia (14%)Infection: Infection (20%)Neuromuscular & skeletal: Weakness (4% to 42%), back pain (5% to 22%)Respiratory: Cough (5% to 26%), dyspnea (3% to 22%), rhinitis (2% to 14%), pharyngitis (12%)Miscellaneous: Infusion related reaction (21% to 40%, chills and fever most common; severe: 1%), fever (6% to 36%) |
| 禁忌               | Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 用法用量           | SC Metastatic Breast cancer & Early breast cancer 3-weekly: 600 mg fixed dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 孕期用藥建議       | Human data suggest risk in 2nd and 3rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 注射劑給藥建議途徑 | SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 注意事項           | 1.本品僅能以皮下注射給予。注射時間應為2-5分鐘。 2.不論患者體重多寡，本品之建議固定劑量為600mg，每3週給藥ㄧ次。 3.注射部位應在左右大腿之間輪替，新的注射部位與舊的注射部位應相距至少2.5公分，且不得在皮膚發紅、瘀青、觸痛或硬塊處注射。 4.第一次皮下注射後6小時以及後續的皮下注射後2小時，應觀察患者是否出現注射相關反應。                                                                                                                                                                                                                                                                                                                                                     |

